Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Stock Information for Coda Octopus Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coda Octopus Group Inc.

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
ZEVASKYN(TM) Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
Bio-Techne's Simple Western(TM) Technology Utilized in Recent FDA Approval of ZEVASKYN(TM) Cell-Based Gene Therapy
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.